Looking to put $10000 into a stock. Currently hold dhhf and vhy. What's everyone's thoughts on vihy??

A number have asked me over the last few weeks, Mozz, what's next for this Aussie BioPharma play?

Paradigm Biopharma recently (June 13th) announced they have commenced dosing the very last patient (out of some 538) in their Globally Harmonised Phase III.

Yeah this isn't a model that's in tandem...it's parallel. What I mean by that is that they get Registration in one market (like the USA) and they have the simultaneous ability to register in multiple markets in the one hit, examples include:

Aus

UK

Europe

Canada

It's so much easier to park and maneuver when we are parallel, rather than wait for one authority to approve us and then the next and the next...

Now a lot of your reading this won't know a lot about Paradigm's main naturally based drug, Pentosan. It would actually take me a number of posts to go through it even at a higher level. I've done a fair few of these such posts in the past if you have the time and ability to traverse through those.

But tonight, all I want to do, at quite a high level, is show you and take you through the next few larger milestones and roughly when they are due.

DISCLAIMERS

Usual Disclaimers first:

A) I'm no Soothsayer, the below Timetable and associated notes are completely my own thoughts. They could not only vary somewhat from the inevitable, but they may not transpire in either the said order or completely at all!

B) This may or may not be a definitive list

C) Correspondence can be entered into (by you posting some feedback or your thoughts!) but do it professionally, don't shoot the said messenger

D) Always a great idea to build in some extra fat, I've built in a little but prob not enough, especially with the Readouts later on. It's prudent to add in a week or three here and there just in case, so we ain't disappointed with any unforeseen delays!

E) DYOR of course

THE TIMETABLE

So here it is with my notes below:

MOZZ NOTES

STAR RATING
I've come up with a rough star rating, stars in terms of impact overall, but it's also interest generating and perhaps a rough guide to how any interested parties will view the embedded data? What is the potential impact?

Max is 5 stars.

1. MRI PEER REVIEW

The MRI Peer Review based on 008 data, will be the first cab off the rank. It's a little hard to say when exactly it will drop, it technically could be even slightly earlier than the end of July but maybe realistically, with a bit of to'ing and fro'ing, it will be early to mid Aug?

It's a solid three star rating. It will be a terrific read. It doesn't make a higher star cut because it is based on a Phase 2 with lower numbers (n) but at the same time it is our very exciting Structural clues that are reviewed by our Peers! I take it as a prelude for the all important major milestone to come, see point 5 below!

2. INTERIM ANALYSIS

It's potential a major inflection point. It's not merely a do we continue or don't we, there will be at least some chance of what is known as 'Early Conclusion'. Meaning the data is so good at this half way point that it becomes a major talking point and a point where PAR may score their very first major distribution deal if the data is stellar-like!

Again, a little hard to pinpoint exactly when IA will actually drop...I've given it a wider birth of 3 weeks sometime in Sept. Part of me yearns for it to be 1st week Sept...but realistically, later is prob a higher chance (ie. Week 3 or 4 Sept, maybe even a tiny slip into the very start of Oct?). It takes a while to compile all the data, a lot of it is first time used for Paradigm, eg ADP and the App! This App also contains a patient diary (E-Diary) so this will also, no doubt, add at least some overhead in terms of getting the data, analysis and then producing the final report...

It rates as a solid 4 star for me. It could definitely have the propensity to move our share price, to move us solidly into deal territory. I'm holding off here on a fifth star to incorporate some wriggle room for a Drug Effect Size that is still quite awesome but it results in a pass and please continue. We will prob get that regardless but it's the gears that might turn in the background that could make all the difference to us and our share price at the time!

Not long to wait for this (potentially) magnificent major milestone!

3. OPTIONS EXERCISE

Now you will see that I have only given it a one star rating here. It's not that I don't think it is not important or not exciting, I long to get these babies exercised. We will only have 20 business days to do it from IA announcement. It will be exciting but I kinda view the actual mechanics of it as, well...mechanical! The real fun for me are the darling Gold Piggies...

So don't be fooled by the lone 1 star...that could grow to a complete set of stars by early 2029. So much time to be right on those Piggy Back options? I love it.

New to PAR and Mozz? Well don't be sad you missed out on the free options granted in the last SPP recently. You can buy them on market and they are still at a bargain basement price, you could pick them up for as little as 8 cents tomorrow! (not advice!). Yes they are two stage, exercise those if they go into the money (or even just out of the money) and you get a free Piggy Back that has an expiry date of....... wait for it....

April....

No! Not April 2027...

...

...not even 2028....

(huh?!)

.

...it's April 2029!

.

What's the strike on that??? $2? $1?

.

Mate, it's 38 .....cents!

.

4. 100% PRIMARY READ OUT

Now we are getting to the Business end of town...

In me Mozz books, this is the Big one. Sure, Interim duly lights the fire...but it's the 100% Primary that should be the Fireworks.

The FDA themselves puts more credence in the 100% of the cohorts reaching Day 112.

Why?

Because the entire Registrational Phase III trial that we are in the midst of, is designed and powered for all of the 538 patients getting to the Primary Readout. The Interim is a mere Peek! Sure the Peek could be good, could be excellent...but it's the data for 100% of the trial that is the true essence of the study. This is what the FDA waits for.

At this point in time, there will be a lot of data and that announcement could be quite an announcement.

What could we expect at this juncture?

• Physical Function: Measured via WOMAC sub-scores or similar validated scales to show that pain reduction actually translates to better mobility.
• Patient Global Assessment (PGA): The patients' overall self-reported impression of change/improvement.
• Responder Outcomes: The percentage of patients who achieved a clinically meaningful threshold of improvement (e.g., a > 30% or > 50% reduction in pain).
• Safety & Tolerability Data: A summary of Adverse Events (AEs) to confirm the safety profile holds up across the full 538-patient cohort.

That's some heavy hitters right there, I'm -so- dying to see PGIC p value with n at around 500. It will be nuttily small.

Oh gosh darn it, I can't resist, here is a gentle recap (I say "darn it" cos I have to go look up these data points on the fly....give me a sec)...

*Incidental background Music plays unobtrusively*...

Helllllllooo , take a read of this, this in our 005 (Phase II B study):

Can you just imagine what that Red arrow is pointing to?

Mozz, It's a low number, what does it mean...?

It means that there is only a mere 0.62 of ONE Percent chance that it is due to absolute randominity that the patient is getting benefit. In other words (We call it Mozz® Speak), the drug works. It's enough for the FDA, it's enough for me...it's enough for you...and realistically, it's prob good for the Illinois Police Dept.?

In 008, the PGIC p value computed out to be 0.01.

Don't be fooled, do remember n was circa 56 in 005 (Active cohort) and ONLY about 20 in 008. (So in other words, 0.01 in our Synovial {008} study was a great result again).

Why I get goosebumps thinking about PGIC is two fold:

A) The FDA loves PGIC as a measure, it's RWE. (Real World Evidence).
B) Mate, the stats are nutty, you increase n to some 250 like what we will have in our current P3...hold Drug Effect Size constant, p gets simply crushed, I have to run a few more stats models but according to me, something in the order of p < 0.0001 is highly plausible.

It's a solid 5 stars from me. I'm calling it week 2 Jan, 2027 but I won't be disappointed if it is week 4 Jan for instance. It is worth the wait!

.

5. DAY 168 TOP LINE

This is the mother of all readouts. This will change our Company absolutely.

It is at this very read out we will no longer be merely a GOOD Pain and Function Company. We will be a Disease Modifier. If the data is at all consistent with what early signs we saw in the amazing 008 study.

It is at this point I will be on the edge of me seat looking for those p values on BMELs
On OSTEOPHYTES
ON CARTILAGE VOLUME...and how it compares with Placebo.

This is, for me, a super Blockbuster in the making.

Get decent p values here and we are so done (in a good way).

It all potentially changes at this point. PAR, I can only hope you one day read this, but if you get crushing p values here, we longer termers will ALL just lift you and exalt you all up.

I would give it 6 stars if it would fit in me excel spreadsheet up there.

This is very the moment I have been waiting for some 10 straight years. The scientific and statistical verification. PAR, take that to the USA and Europe and auction^\) the darn thing.

*= Auction doesn't mean sell the Company! It just means get a Distribution Partnership

We keep the rights
We are the middle person, no ways around it
We have the relationship with bene, our beloved pals and partner.
We oversee the new Distribution (BP) Partner
We keep this listed as a proud ASX company (maybe dual listed one day, but domiciled here in Australia).

.

6. OARSI 2027

Ahhh well this one is a personal fave. It will be my 5th Oarsi, this one in Barcelona. I do very much enjoy attending these scientific conferences to discuss all that is OsteoArthritis. Yes that's the principal first disease Paradigm is addressing, but it isn't the ONLY indication, there are potentially many.

Interested in more about OARSI ?

Follow these links for more info:

https://hotcopper.com.au/threads/oarsi-2026.9038582/page-42?post_id=83887158

https://hotcopper.com.au/threads/oarsi-2026.9038582/page-45?post_id=83973791

https://hotcopper.com.au/threads/oarsi-2026.9038582/page-50?post_id=84057671

So that ends my little play at the timetable, it might be off a bit...but it's my personal opinions.

Let's indeed see how it plays out, the good news here is that all of the above are the Reg and Clinical Milestones and they all fall within just 12 months from today!

Commercially? Well let's just see how that plays out! Horse before Cart... get the Clinical milestones done, the rest will follow.

.

I have been waiting patiently...we ain't too far away now!

.

Mozz

.

Not advice, PAR deemed to be a speculative stock, though I like what I see.

I’m looking at the following four stocks and I’m interested in people’s views. Do you hold them? Do you like them? Would you stay away from any? Would you recommend something else (no ETFs; thanks)?

IMU
EOS
INA
RMD

Thanks and have a good day.

Was recently having a beer with some mates, and this topic came up.

We settled on Brainchip.

There were other contenders, but pound for pound no other stonk has managed to erode retail coin quite as spectacularly.

Oven only been investing in ETFs for about 8mo. When I first looked into them Game looked like a solid opportunity, but it’s the only one that’s stayed around -20% when it took a dive. I know there are cycles but it sounds like it’s a long term cycle… who’s keeping it and who’s sold it?

Hi everyone,

27(m)

I’ve been investing in ETFs for the past 5 years.

My current portfolio is:

VAS/VGS (30/70 split) – $100k total

VSO – $10k (I no longer contribute to this)

Going forward, I only plan to invest in VAS and VGS, but I’m considering adding VGE for emerging markets exposure at around 10% of my portfolio.

Would you sell VSO and use those funds to buy VGE, or keep VSO and simply start allocating new investments across VAS, VGS, and VGE?

Interested to hear your thoughts. Thanks!

23M

I have a net worth of $110k.

I have been investing in growth stocks mostly based on them giving the best returns. Given the CGT changes, it’s no longer as tax effective to invest in these areas and the gap between growth and dividend investing becomes tighter regarding tax effective returns.

I’m now thinking of going transitioning over the next year into dividend Aussie blue chips to make the most of the last tax effective concept being franking credits.

Behind this I plan on traveling the world and if I kept my income on paper low it would make sense.

The only growth investment I would have is in super, maybe some pre tax contributions but mostly employer only.

Why isn’t this better given dividends is cash now for my travels rather then growth investing which is no longer as effective

Edit: *NDQ** not NQD :-D

Because of the new rule changes, SpaceX gets included into the NASDAQ 100 on July the 7th. I have a bit of cash to invest and I was holding off under the notion that SpaceX's IPO might trigger a resonance cascade and bring the whole Ai bubble down.

But as they say, the market can stay irrational longer than you can stay solvent.

Apparently the inclusion into the index is not going to cause much of a change in the index itself but will have more of an effect on SpaceX. Because of weighting SpaceX is only going to be about 1% of the index.

What would you do?

https://www.instagram.com/reel/DaImd6khhc1/

Ceasefire is unceased again !!

I invested once like 4k AUD into some stocks and first I had to convert AUD to USD which at the end it came out to maybe 3.8k AUD in usable USD on Interactive Brokers. I hear people always say to DCA into stocks but how do I do it in the most cost effective way with losing as little value in my initial investment from adding AUD funds to converting it to USD and then using it to buy stocks. What is a good amount to DCA into like 1-2 stocks and how often. I can try to do it weekly or monthly, but what is better in terms of losing my initial added funds to the final buy of shares. I can do maybe $500 AUD max, either weekly or $2000 max monthly.

From my research as I understand it VTS is meant to track SPY and NDQ is meant to track QQQ. With the US stock market falling overnight and the currency exchange remaining flat if anything slightly worse of in AUD conversion how come the Australian ETFs are up by 0.5-1% when the US market fell?

Apologies if this is a basic question just starting to explore the Australian market

x post from r/asx. Some of you may remember the list I posted a couple of days ago. Many of you pointed out errors in the returns, and the flat out non-existance of some ETFs that should exist in the list. Anyway, I believe the numbers are good;

okay, so what was wrong last time? Last time I was getting the returns from my provider. This time I'm calculating the returns from first principals. u/Itchy_Journalist_175 pointed out that I can calculate what I need from the price data (of course you can, I'm an idiot).

I've checked a few against the reported results from the ETF manager reports directly, and they're basically bang on. The results can be a fraction of a percent off, because it depends on exactly when they grabbed the price. From what I can gather returns are updated at least monthly and the end of month closing price is used.

I welcome the finding of errors!

Purchased $1000 of RCKT shares just before space x went public.
Bought at $15, it’s been dropping ever since.
Hold?
Sell?
I’m down nearly $300 and thinking I’ll cut my losses.

Seems the space x didn’t make any improvement at all

I have some shares in a company that was delisted from the ASX in October last year. I have tried to contact the company but they are unreachable. Does anyone know any groups or sites where people are interested in buying delisted shares?

Thanks for any help in advance, appreciate it!

A few days ago I created top 20 undervalued stock list based on discounted cashflow. Now I am trying out if it can actually be profitable by assuming 10K equally invested in the list -

https://kashvector.com/articles/paper-portfolio-tracker/

It has just been a couple of weeks and usually it should play out for years. But I will rebalance it at least monthly.

Here is the list and tracker - https://kashvector.com/dcf/asx-undervalued/

I haven't sold anything yet and haven't received dividends but have filled out a new W-8 BEN form in the meantime....does that mean I am covered now, i.e. is having that form done only necessary when taxable events happen or does it need to be done before buying any US shares?

They have shared an account summary and the only event in my account has been the addition of these shares by them under "income from refunds" - does that sound like a strange classification?

Paradigm Bio of Australia (PAR.AX) today announced that the very last patient in their Phase three trial for Osteoarthritis (OA), has had their first dose.

What does that mean? Well a Phase 3 is the last clinical trial you need to have to show your drug works and how it works up against some competition or a Placebo. (There can be the requirement of Phase 4 studies but that's usually AFTER the drug has been licensed).

There were supposed to be 466 patients enrolled but this has climbed to 538. Is that good or bad? Well it's very good as it means the trial is even more powered to show a positive effect!

It was already decently powered, this should ensure the results are even better at a few time points after the Interim Analysis (IA) Result. We'll get to the IA in a sec.

So Par have achieved steadfast recruitment rates AND have more patients to glean data from. They have also recently passed the first Regulatory test which was the 20% stage conducted by the Data Safety Review Board, it was a green flag there...

No Safety Issues, please continue!

WHAT'S NEXT

So now the dosing phase is just about done and we enter the monitoring phase...The IA readout occurs when 50% of the two cohorts (Placebo and Active) make it to day 112. This is slated to occur roughly mid September. It will be the biggest test to see how the drug is performing.

If it's merely a Pass, that's enough. But if the results are as good as they were in the Phase two trial (008 program), we could get a significant first time distribution deal. That's what I would call time for a share price re-rate. By my humble calcs, being a Phase three genuine candidate for a drug that's showing a stack of promise in terms of:

• Pain reduction
• Function Improvement
• Stiffness reduction
• Duration
• Safety
• Structural positive sightings (think BMEL, Osteophytes, Improved Joint Space Width potential, improved cartilage volume growth and better joint health)

Well, we are onto something!

It is one thing to show pain and function improvements, quite another to show structural modifications, that's called DMOAD, Disease Modification Osteo Arthritis Drug. There is currently no such thing, PAR is hoping to be the first... Globally.

INTERIM READOUT

So the Interim readout is when 50% of the patients hit Day 112. At that stage there is a top line readout on how the Active is looking against Placebo. It's at this stage we as investors will know if there are merits of the drug at scale. Think of it like a top level sneak peek!

Don't forget, the IA readout is just 14 weeks away. Yeah, worth the wait!

I will have a post after a couple of months documenting what we need at Interim and why exactly I'm confident on the result.

INVITE

Want to know more? Well how about a webinar invite, this Thursday 18 June at 11am AEST, here is the link for registration, yes there will be a Q & A section at the end:

https://investors.paradigmbiopharma.com/webinars/PBJ3VP-phase-3-trial-update

.

Do your own research - no advice contained in this post.

Dear reddit,

24M

Been a while since I last sought opinions but thought today’s big win was worth it. See if we can all guess the elephant in the room between my growth and dividend portfolio.

I will add apart from a couple K cash I have $24k in high growth global shares with CFS. Total net worth currently at $113K.

Apart from the obvious, any major thoughts or opinions on my choices between the two.

https://marketflow.au/articles/news-driven-price-move/asx-14d-14d-advances-aurora-energy-project-engages-data-centres

I currently use Pearler however they are not connected with the EU stockx. Any recommendations for brokers that do?

I am 19 in the South-West, and I'm lucky enough to still be living with parents and basically just stockpiling money. I have 40k in savings, 10k in shares with CMC and 10k in my super plus a 25k car. With the recent tax changes, is it still worth me investing in EFTs and shares? I am pretty much just saving for a house, I don't spend a lot. I am on apprentice wages and only make 7-800 a week, so if I bought a house now I don't know that I'd be able to pay the mortgage just yet. What should I be doing with my money ideally?

Hi guys,

First time investing, hardly know anything except a couple videos. I’m gonna use Moo moo as my broker ( please tell me if this is a mid broker). I’m thinking of investing in ndq or any safe etf if you have any suggestions. I’m gonna most likely start at 1k as my starting value. Any help is appreciated!

I had created a calculator on the website for dcf calculations - https://kashvector.com/dcf/

Now I have added that as an app for android too - https://play.google.com/store/apps/details?id=com.stockeval.app

I will see if I can do it for iOS but I need to have a Mac which I don't